Q (haiku): For patients with the EML4-ALK fusion gene in lung cancer how do the different fusion variants affect their long-term quality of life and risk of developing a secondary cancer?

═ answer (success)
I appreciate the question, but I need to clarify what cBioPortal can and cannot address here.

**What I can help with:**
cBioPortal stores genomic alteration data, including EML4-ALK fusion variants in lung cancer studies. I can query:
- Frequency of EML4-ALK fusions and their specific breakpoint variants in lung cancer cohorts
- Co-occurring mutations in EML4-ALK-positive patients
- Clinical attributes like age, stage, or treatment available in the database
- Links to survival data for those cohorts

**What is out of scope:**
- **Quality of life outcomes** — cBioPortal does not store QoL metrics, functional status, symptom burden, or patient-reported outcomes
- **Secondary cancer risk** — cBioPortal does not track second malignancies, therapy-related toxicity, or long-term treatment sequelae; it captures cancer genomics at one timepoint, not longitudinal treatment effects
- **Variant-specific prognosis** — Linking specific EML4-ALK breakpoint variants to distinct clinical trajectories requires specialized ALK databases (e.g., ALK Fusion Variant Database) and prospective cohort analysis, not cross-sectional genomic data

**Next steps:**
If you'd like to explore EML4-ALK in cBioPortal, I can:
1. **Query** the frequency and types of EML4-ALK fusions in lung cancer studies
2. **Navigate** to the Structural Variants or Mutations tab to visualize these fusions
3. **Link** external resources (if available in cBioPortal's resource tables) to specialized ALK registries

Would you like me to proceed with what cBioPortal can provide — e.g., EML4-ALK prevalence and co-mutation patterns in lung adenocarcinoma?